Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, and participate in one-on-one investor meetings. The company's lead product ZELSUVMI (berdazimer) showed 17% quarter-over-quarter revenue growth, reaching $10.7 million in Q1 2026.
05/28/2026, 5:00 PM • GlobeNewswire
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Pelthos Therapeutics Inc. (PTHS) announced the acquisition of Xeglyze® (abametapir), an FDA-approved topical treatment for head lice, from Australian biotech company Hatchtech Pty Ltd. for $1.8 million. The acquisition adds a complementary product to Pelthos' portfolio with no future milestone or royalty payments owed. The company plans to relaunch Xeglyze in the first half of 2027, leveraging its existing commercial infrastructure.
01/05/2026, 7:30 AM • Benzinga
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Pelthos Therapeutics Inc. (NYSE American: PTHS) announced the appointment of veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Einhorn brings over four decades of experience in investment banking, capital markets, and C-level finance roles at life science companies. He will serve on the Audit Committee and Compensation Committee. The appointment increases the Pelthos Board to eight directors.
12/23/2025, 5:57 PM • GlobeNewswire
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.
12/09/2025, 7:00 AM • GlobeNewswire
Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.
12/04/2025, 7:00 AM • GlobeNewswire
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
Pelthos Therapeutics will hold a conference call on November 13, 2025, at 8:00 a.m. Eastern Time to discuss its third quarter financial results for the period ended September 30, 2025.
11/05/2025, 8:00 AM • GlobeNewswire
